Biologics Drug Discovery Market Market Size, Share and Growth Analysis 2025 to 2034
Segmentation of Biologics Drug Discovery Market
Biologics Drug Discovery Market by Method
· Target Identification/Validation
· Hit Generation/Validation
· Lead Identification
· Lead Optimization
Biologics Drug Discovery Market by Manufacturing Type
· In-House Manufacturing
· Outsourced Manufacturing
Biologics Drug Discovery Market by Type
· Monoclonal Antibodies
· Recombinant Proteins
· Other Biologics
Biologics Drug Discovery Market by Region
North America-
· The US
· Canada
Europe-
· Germany
· The UK
· France
· Italy
· Spain
· Rest of Europe
Asia-Pacific-
· China
· Japan
· India
· South Korea
· Southeast Asia
· Rest of Asia Pacific
Latin America-
· Brazil
· Argentina
· Mexico
· Rest of Latin America
Middle East & Africa-
· GCC Countries
· South Africa
· Rest of the Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Biologics Drug Discovery Market Snapshot
Chapter 4. Global Biologics Drug Discovery Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global Biologics Drug Discovery Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on BIOLOGICS DRUG DISCOVERY MARKET Industry Trends
Chapter 5. Biologics Drug Discovery Market Segmentation 1: By Method, Estimates & Trend Analysis
5.1. Market Share by Method, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Method:
5.2.1. Target Identification/Validation
5.2.2. Hit Generation/Validation
5.2.3. Lead Identification
5.2.4. Lead Optimization
Chapter 6. Biologics Drug Discovery Market Segmentation 2: By Manufacturing Type, Estimates & Trend Analysis
6.1. Market Share by Manufacturing Type, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Manufacturing Type:
6.2.1. In-House Manufacturing
6.2.2. Outsourced Manufacturing
Chapter 7. Biologics Drug Discovery Market Segmentation 3: By Type, Estimates & Trend Analysis
7.1. Market Share by Type, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type:
7.2.1. Monoclonal Antibodies
7.2.2. Recombinant Proteins
7.2.3. Other Biologics
Chapter 8. Biologics Drug Discovery Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global Biologics Drug Discovery Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Method, 2021-2034
8.2.3. North America Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing Type, 2021-2034
8.2.4. North America Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
8.3. Europe
8.3.1. Europe Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Method, 2021-2034
8.3.3. Europe Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing Type, 2021-2034
8.3.4. Europe Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Method, 2021-2034
8.4.3. Asia Pacific Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing Type, 2021-2034
8.4.4. Asia Pacific Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
8.5. Latin America
8.5.1. Latin America Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Method, 2021-2034
8.5.3. Latin America Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing Type, 2021-2034
8.5.4. Latin America Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Method, 2021-2034
8.6.3. Middle East & Africa Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing Type, 2021-2034
8.6.4. Middle East & Africa Biologics Drug Discovery Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Alloy Therapeutics, Inc.
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Charles River Laboratories International, Inc.
9.2.3. Regeneron Pharmaceuticals, Inc.
9.2.4. WuXi Biologics (Cayman) Inc.
9.2.5. AbbVie Inc.
9.2.6. Amgen, Inc.
9.2.7. Astellas Pharma Inc.
9.2.8. AstraZeneca Plc
9.2.9. Bristol-Myers Squibb
9.2.10. Novo Nordisk A/S
9.2.11. Novartis AG
9.2.12. Evotec SE
9.2.13. Eli Lilly and Company
9.2.14. GenScript Biotech Corporation
9.2.15. Gilead Sciences, Inc.
9.2.16. Merck KGaA
9.2.17. Johnson & Johnson
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
The Biologics Drug Discovery Market Size is valued at US$ 22.9 Bn in 2025 and is predicted to reach US$ 54.9 Bn by the year 2034 at an 10.2% CAGR over the forecast period.
The major players in the Biologics Drug Discovery market are Alloy Therapeutics, Inc., Charles River Laboratories International, Inc., Regeneron Pharmaceuticals, Inc., WuXi Biologics (Cayman) Inc., AbbVie Inc., Amgen, Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol-Myers Squibb, Novo Nordisk A/S, Novartis AG, Evotec SE, Eli Lilly and Company, GenScript Biotech Corporation, Gilead Sciences, Inc., and Merck KGaA.
The primary Biologics Drug Discovery market segments are Method, Manufacturing Type, and Type.
North America leads the market for Biologics Drug Discovery due to the strong combination of cutting-edge research facilities, well-funded biotechnology businesses, and consistent government backing for novel therapeutics.